Shopping Cart
- Remove All
- Your shopping cart is currently empty
Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $415 | In Stock | |
5 mg | $1,230 | In Stock | |
10 mg | $1,990 | In Stock |
Description | Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN). |
In vivo | Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can significantly inhibit tumor growth in the U87MGde2-7 glioblastoma multiforme (GBM) model and A431 squamous cell carcinoma model of Nu/Nu mice. Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can inhibit tumor growth and pEGFR levels in the EGFRvIII-positive GBM-SN0199-PDX model of NSG mice. [1] |
Synonyms | ABT-806, ABT806 |
Cas No. | 1471999-69-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.